Yes, very small (orphan) market. But the key is to get the drug on the market as soon as possible and try to expand indications later.
Side effects are very benign in general, so key will be finding right combinations. Unclear to me what the impact will be of increasing dosage - you seem to get about as many responses at low dose as at high dose. Might be very hard to figure out why some people respond and others don't. (compare PD-1).
It might be that the right combo will prove to be with something like IFN-gamma or IL-2 at the right time rather than the fancier IO drugs.
As I've said repeatedly, this drug needs to be in the hands of a big company.
News 
Market Data 
Discover 
AI
